The virtual CHIEF-HF trial has demonstrated a significant positive effect of canagliflozin on heart failure symptoms without the need for in-person clinic visits, the investigators report in Nature Medicine.
Findings from the TriMaster trial suggest that stratification of people with type 2 diabetes based on clinical features may help to guide the choice of second- or third-line drug for those who require treatment intensification after metformin.
Canagliflozin may reduce the risk for hyperkalemia, without increasing hypokalemia, in people with type 2 diabetes and chronic kidney disease receiving renin–angiotensin–aldosterone system inhibitors, shows a CREDENCE post-hoc analysis.
Adding canagliflozin to current standard of care improves survival, increases quality-adjusted life–years, and reduces treatment costs for people with type 2 diabetes treated in England over a 10-year period, research suggests.
Treatment with the SGLT2 inhibitor canagliflozin is associated with a reduced risk for anemia-related outcomes among people with type 2 diabetes and chronic kidney disease, suggests a post-hoc analysis of the CREDENCE trial.